Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of SAGE-718 in Huntington's disease
ISRCTN47421449Phase 3Completed
- Sponsor
- Sage Therapeutics
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, open-label trial of dalzanemdor in Huntington disease (HD) (3 arms), sponsored by Sage Therapeutics. Primary endpoints: Treatment-emergent adverse events, Withdrawals due to adverse events and 2 more. Started Dec 2022; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on ISRCTN47421449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47421449.